Johnson and Johnson 2015 Annual Report Download - page 14

treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products; SIRTURO®
(bedaquiline), a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>18 years) with
pulmonary multi-drug resistant tuberculosis (MDR-TB); CONCERTA®(methylphenidate HCl) extended-release tablets CII,
a treatment for attention deficit hyperactivity disorder; INVEGA®(paliperidone) extended-release tablets, for the treatment
of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA®/XEPLION®(paliperidone palmitate), for the
treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA®(paliperidone palmitate), for the
treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA®for at least four
months; RISPERDAL CONSTA®(risperidone long-acting injection), for the treatment of schizophrenia and the
maintenance treatment of Bipolar 1 Disorder in adults; VELCADE®(bortezomib), a treatment for multiple myeloma and for
use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with
previously untreated mantle cell lymphoma; ZYTIGA®(abiraterone acetate), used in combination with prednisone as a
treatment for metastatic castration-resistant prostate cancer; IMBRUVICA®(ibrutinib), an oral, once-daily therapy
approved for use in treating certain B-cell malignancies, or blood cancers, and Waldenström’s Macroglobulinemia;
DARZALEXTM (daratumumab), for the treatment of double refractory multiple myeloma; YONDELIS®(trabectedin), for the
treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-
containing regimen; PROCRIT®(epoetin alfa, sold outside the U.S. as EPREX®), to stimulate red blood cell production;
XARELTO®(rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to
pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment and reduction of risk of recurrence of DVT
and PE; INVOKANA®(canagliflozin), for the treatment of adults with type 2 diabetes; and INVOKAMET®/VOKANAMET®
(canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the
treatment of adults with type 2 diabetes. Many of these medicines were developed in collaboration with strategic partners
or are licensed from other companies and maintain active lifecycle development programs.
Medical Devices
The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular,
diabetes care and vision care fields. These products are distributed to wholesalers, hospitals and retailers, and used
principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. They include
orthopaedic products; general surgery, biosurgical, endomechanical and energy products; electrophysiology products to
treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products,
such as blood glucose monitoring and insulin delivery products; and disposable contact lenses.
Geographic Areas
The business of Johnson & Johnson is conducted by more than 250 operating companies located in 60 countries,
including the U.S., in virtually all countries throughout the world. The products made and sold in the international business
include many of those described above under “– Segments of Business – Consumer,” “– Pharmaceutical” and “– Medical
Devices.” However, the principal markets, products and methods of distribution in the international business vary with the
country and the culture. The products sold in international business include those developed in the United States and by
subsidiaries abroad.
Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities
because the investment and commercial climate may be influenced by financial instability in international economies,
restrictive economic policies and political and legal system uncertainties.
Raw Materials
Raw materials essential to the Company’s business are generally readily available from multiple sources. Where there are
exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the
financial results of the Company.
Patents
The Company’s subsidiaries have made a practice of obtaining patent protection on their products and processes where
possible. They own or are licensed under a number of patents relating to their products and manufacturing processes,
which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. Sales
2•Johnson & Johnson 2015 Annual Report